Research Topics
| Brigitte C WidemannSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Phase I study of O6-benzylguanine and temozolomide administered daily for 5 days to pediatric patients with solid tumorsKatherine E Warren
National Cancer Institute Neuro Oncology Branch, Building 82, Room 219, 9030 Old Georgetown Rd, Bethesda, MD 20892 8200, USA
J Clin Oncol 23:7646-53. 2005....
A phase I trial and pharmacokinetic study of sorafenib in children with refractory solid tumors or leukemias: a Children's Oncology Group Phase I Consortium reportBrigitte C Widemann
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 18:6011-22. 2012....
Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumorsBrigitte C Widemann
Pediatric and Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 27:550-6. 2009....- Understanding and managing methotrexate nephrotoxicityBrigitte C Widemann
Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10 CRC Room 1 5750, Bethesda, Maryland 20892 1101, USA
Oncologist 11:694-703. 2006..7% (range, 84%-99.5%). The early administration of CPDG(2) in addition to LV may be beneficial for patients with MTX-induced renal dysfunction and significantly elevated plasma MTX concentrations... - Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromasBrigitte C Widemann
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
J Clin Oncol 24:507-16. 2006.... - Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumorsBrigitte C Widemann
Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
Curr Oncol Rep 11:322-8. 2009..This knowledge, coupled with the availability of preclinical MPNST models, likely will accelerate the development of effective treatments for this malignancy... - Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcomeBrigitte C Widemann
Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892 1101, USA
J Clin Oncol 28:3979-86. 2010..To assess the role of the recombinant bacterial enzyme, glucarpidase (carboxypeptidase-G(2)), leucovorin, and thymidine in the management and outcome of patients with high-dose methotrexate (HDMTX) -induced nephrotoxicity... - Phase 1 trial and pharmacokinetic study of the farnesyl transferase inhibitor tipifarnib in children and adolescents with refractory leukemias: a report from the Children's Oncology GroupBrigitte C Widemann
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
Pediatr Blood Cancer 56:226-33. 2011..The objectives of this trial were to define the toxicity profile, dose, pharmacokinetics, and pharmacodynamics of the farnesyl transferase (FTase) inhibitor, tipifarnib, in children and adolescents with hematological malignancies... - Merlin PAKs a punchBrigitte C Widemann
Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10, Room 13C103, Bethesda, Maryland 20892-1928, USA
Cancer J 10:8-11. 2004 - A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumorsElizabeth Fox
Authors Affiliations Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 14:1111-5. 2008..To determine the toxicity profile, dose-limiting toxicities (DLT), and maximum tolerated dose (MTD) of ABT-751 administered orally once daily for 21 days, repeated every 28 days in a pediatric population... - Treatment of accidental intrathecal methotrexate overdose with intrathecal carboxypeptidase G2Brigitte C Widemann
Pediatric Oncology Branch, Pediatric Oncology Branch, National Cancer Institute, 10 Center Dr, Bldg 10, Rm 13C103, Bethesda, MD 20892 1920, USA
J Natl Cancer Inst 96:1557-9. 2004..Intrathecal CPDG2 is well tolerated, rapidly decreases CSF methotrexate concentrations, and appears to be efficacious for treating accidental intrathecal methotrexate overdoses... - Characteristics and outcome of pediatric patients enrolled in phase I oncology trialsAerang Kim
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10 CRC, Room 1 3872, Bethesda, MD 20892, USA
Oncologist 13:679-89. 2008..To describe the characteristics of pediatric subjects who enroll in phase I trials, to determine the associations between pre-enrollment characteristics and the risk for toxicity, and to analyze response and survival outcomes... - Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromasAerang Kim
Pediatric Oncology Branch, NCI, CCR, Bethesda, Maryland, USA
Pediatr Blood Cancer 60:396-401. 2013..Monitoring long-term toxicities such as effects on growth and obtaining additional pharmacokinetic data were of importance due to the young age and long duration of therapy seen in previous phase I trials in children with NF1... - The plasma and cerebrospinal fluid pharmacokinetics of sorafenib after intravenous administration in non-human primatesAerang Kim
Pediatric Oncology Branch, Pharmacology and Experimental Therapeutics Section, National Cancer Institute, 10 Center Drive, Building 10 CRC, Bethesda, MD 20892, USA
Invest New Drugs 30:524-8. 2012..We evaluated the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of sorafenib after an intravenous (IV) dose in a non-human primate (NHP) model... - The plasma and cerebrospinal fluid pharmacokinetics of the platinum analog satraplatin after intravenous administration in non-human primatesLeigh Marcus
National Cancer Institute, Pediatric Oncology Branch, 10 Center Drive, Building 10 CRC, Room 1 5742, Bethesda, MD 20892 1101, USA
Cancer Chemother Pharmacol 69:247-52. 2012..7 and 2.6%, respectively). We evaluated the plasma and CSF pharmacokinetics (PK) of satraplatin after an intravenous (IV) dose in NHP... - Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomasElizabeth Fox
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland 20892, USA
Clin Cancer Res 15:7361-7. 2009..To compare the effectiveness, tolerance, and pharmacokinetics of a single dose of pegfilgrastim to daily filgrastim in children and young adults with sarcomas treated with dose-intensive combination chemotherapy... - Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphomaElizabeth Fox
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
Blood 111:566-73. 2008..15 mg/kg per day. The response rate in children with relapsed APL is similar to the response rate in adults. This trial was registered as #NCT00020111 at www.ClinicalTrials.gov... - High-dose methotrexate-induced nephrotoxicity in patients with osteosarcomaBrigitte C Widemann
Pediatric Oncology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892 1920, USA
Cancer 100:2222-32. 2004.... - A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumorsElizabeth Fox
Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 12:4882-7. 2006..To determine the toxicity profile, dose-limiting toxicities, and maximum tolerated dose of ABT-751 administered orally once daily for 7 days, repeated every 21 days... - Automated volumetric growth plate measurement using magnetic resonance imaging for monitoring skeletal toxicity in children treated on investigational drug trialsAerang Kim
Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
Clin Cancer Res 17:5982-90. 2011..Careful evaluation of skeletal toxicity in the clinical development of targeted therapies for children is required. We validated a novel method to measure the growth plate volume using MRI... - A phase I trial and pharmacokinetic study of tipifarnib, a farnesyltransferase inhibitor, and tamoxifen in metastatic breast cancerPeter F Lebowitz
Medical Oncology Clinical Research Unit, National Cancer Institute NIH, 9000 Rockville Pike, Bethesda, MD 20892, USA
Clin Cancer Res 11:1247-52. 2005..We studied the safety and toxicity of tipifarnib in combination with tamoxifen in metastatic breast cancer. The pharmacokinetics and pharmacodynamics of tipifarnib were also assessed... - Plasma and CNS pharmacokinetics of O4-benzylfolic acid (O4BF) and metabolite in a non-human primate modelMeredith K Chuk
Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Building 10 Rm 1W 5750, Bethesda, MD 20892, USA
Cancer Chemother Pharmacol 67:1291-7. 2011..We studied plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of O(4)BF in a non-human primate model... - Experiences of families with a child, adolescent, or young adult with neurofibromatosis type 1 and plexiform neurofibroma evaluated for clinical trials participation at the National Cancer InstituteStaci Martin
Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
Contemp Clin Trials 32:10-5. 2011..However, little is known about the experiences of families with children with NF1 participating in clinical trials... - Phase I trial and pharmacokinetic study of lexatumumab in pediatric patients with solid tumorsMelinda S Merchant
National Cancer Institute, National Institutes of Health, 10 Center Dr, Building 10 CRC, Room 1W 3750, Bethesda, MD 20892 1104, USA
J Clin Oncol 30:4141-7. 2012..Lexatumumab is an agonistic, fully human monoclonal antibody against tumor necrosis factor-related apoptosis-inducing ligand receptor 2 with preclinical evidence of activity in pediatric solid tumors... - Bone mineral density in children and young adults with neurofibromatosis type 1Maya B Lodish
Section on Endocrinology and Genetics, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
Endocr Relat Cancer 19:817-25. 2012..90; P=0.036). Plexiform neurofibroma burden was negatively correlated with LS BMAD (r(s)=-0.36, P=0.01). In pediatric and young adult patients with NF-1, LS BMAD was more severely affected than the FN BMAD or whole-body BMC/height... - Evaluation and treatment of fever in the non-neutropenic child with cancerWanda Salzer
Pharmacology and Experimental Therapeutics Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA
J Pediatr Hematol Oncol 25:606-12. 2003..To document the current approach to the evaluation and treatment of febrile non-neutropenic children with cancer by surveying American Society of Pediatric Hematology/Oncology (ASPHO) members... - Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromasDusica Babovic-Vuksanovic
Department of Medical Genetics, Mayo College of Medicine, Rochester, MN, USA
Pediatr Neurol 36:293-300. 2007..The second dose level was the pharmacokinetically comparable dose and is being used in an ongoing phase II trial of pirfenidone for children with neurofibromatosis 1 and progressive plexiform neurofibroma... - Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1Victor F Mautner
Department of Maxillofacial Surgery, University Hospital Eppendorf, Hamburg, Germany
Neuro Oncol 10:593-8. 2008..Close surveillance of these high-risk patients may permit earlier diagnosis and more effective treatment of MPNSTs that develop... - The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progressionMichael J Fisher
Division of Oncology, The Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
J Neurooncol 87:165-71. 2008..We hypothesized that PN tumors with high metabolic activity as demonstrated by FDG-PET are more likely to progress in the following year...